Takeda's Narcolepsy Drug Shows Promise in Late-Stage Trials

Takeda Pharmaceutical's experimental drug for narcolepsy, oveporexton, has shown promising results in late-stage clinical trials. The drug's potential lies in its ability to address the underlying cause of this chronic sleep disorder, making it a potentially groundbreaking treatment option.

The clinical trials involved patients taking oveporexton for a period of 12 weeks. The results indicated significant improvements in several key areas. Participants experienced enhanced daytime alertness, a reduction in the frequency of cataplexy episodes (sudden muscle tone loss), and a general improvement in their overall quality of life. These findings were presented at the World Sleep Congress in Singapore.

The studies also noted the occurrence of certain side effects. While no serious adverse events were reported, the most frequently observed side effects included insomnia, as well as an increase in urinary urgency and frequency.